Evidence map›Paper›PMID 37037708›Full record

SynthesisVaccine2023

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.

Yuxuan Hu, Yanning Wang, Taihang Shao, Wenxi Tang, Kerong Hu, Yujie Zhou, Liyun Miao, Jing Liu, Bin Wang, Wenying Yu

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yuxuan HuInstitute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 211198, PR China.
Yanning WangClinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, PR China.
Taihang ShaoDepartment of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, PR China.
Wenxi TangDepartment of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, PR China.
Kerong HuDepartment of Infectious Diseases, Huangshi Love&Health Hospital, Huangshi 435000, PR China.
Yujie ZhouDepartment of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing 210008, PR China.
Liyun MiaoDepartment of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing 210008, PR China.
Jing LiuClinical Laboratory, Nanjing Yuhua Hospital (Yuhua Branch of Nanjing First Hospital), Nanjing 210039, PR China. Electronic address: hb670505@163.com.
Bin WangClinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, PR China. Electronic address: wangbin022800@126.com.
Wenying YuInstitute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 211198, PR China. Electronic address: ywy@cpu.edu.cn.
China Pharmaceutical University · CNNanjing Drum Tower Hospital · CNHuangshi Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHere, we systematically assessed the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens. MATERIALS AND

methodsWe evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165.

resultsEleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety. DISCUSSION: Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety.

Indexed as

BNT162 VaccineCOVID-19Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansImmunoglobulin GVaccinationAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GCOVID-19Heterologous vaccinationImmunogenicityMeta-analysisSARS-CoV-2

Identifiers

PMID37037708
PMCPMC10060199
OpenAlexW4361276026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.